Eli Lilly: Sticking With A $1000 Target Ahead Of Q3 Earnings, New Trading Range
Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...
Barchart on MSN14h
Snag This Biotech Stock Before November, Here's Why
As retail investors flock to Viking Therapeutics, the biotech firm is also catching the eye of billionaire fund managers like ...
Yahoo Finance19h
Viking Therapeutics, Inc. (VKTX): Biotech Breakthrough or Short Sellers’ Target?
This highlights the company’s ability to keep up with all of its pipeline programs. However ... Their VK2735 drug is a GLP-1 dual agonist being developed for patients with obesity. During the quarter, ...
Does ‘nature’s Ozempic’ really work? Trendy GLP-1 supplements are designed to supercharge weight loss for a fraction of the price
Why fork over thousands of dollars a month for prescription weight loss jabs when store-bought supplements claim to have the ...
Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects
Pemvidutide's potential in obesity and MASH, combined with lean mass preservation, could make it a market leader in the ...